

# Navigating the Future: US Pneumococcal Vaccine Market to Sail to US\$ 6,511.79 Million by 2034 with a 2.3% CAGR

*The prohibition of serious contamination such as pneumonia, meningitis, and bloodstream contamination are driving the US pneumococcal vaccine market.*

NEW YORK CITY, NY, UNITED STATES, December 10, 2024 /

EINPresswire.com/ -- The [US pneumococcal vaccine market](#) report assesses the competitive scenario of the market, examining all the established players and new market entrants.

The market for the US pneumococcal vaccine is on a growth trajectory. The market, valued at USD 5,239.27 million in 2024, is poised to reach USD 6,511.79 million by 2034. It is anticipated to register a CAGR of 2.3% from 2025 to 2034.



The image shows the cover of a market research report titled "US Pneumococcal Vaccine Market" by POLARIS MARKET RESEARCH. The cover features a blurred background of a healthcare professional in blue scrubs holding a small vial labeled "Coronavirus SARS-CoV-2". In the bottom right corner, there is a circular icon with an upward arrow and the text "2.3% CAGR from 2025 - 2034". Below the image, the text "US Pneumococcal Vaccine Market" is displayed.

□□□□□□ □□□□□□□□□□□□□□:

Pneumococcal vaccine is a vaccine to prohibit pneumococcus bacteria contamination. These bacteria are a prominent cause of ear contamination, strep throat contamination, grave pneumonia, meningitis, or blood contamination globally. These vaccines assist the body to generate antibodies that assist the body to protect against these bacteria. This vaccine is approved for persons two years of age and adults with health issues.

□□□□□□□□ □□□□ □□□□□□ □□ □□□□ □□ □□□□□□:

[https://www.polarismarketresearch.com/industry-analysis/us-pneumococcal-vaccine-market/request-for-sample?utm\\_source=EIN&utm\\_medium=EIN&utm\\_campaign=EIN&utm\\_id=01](https://www.polarismarketresearch.com/industry-analysis/us-pneumococcal-vaccine-market/request-for-sample?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01)



Firms are partnering with local governments and non-governmental bodies to advance productive vaccines for prohibiting pneumonia.”  
*Polaris Market Research*

The vaccine is for injection into a muscle or beneath the skin. It is provided by a healthcare expert. A replica of Vaccine Information Statements will be provided prior to each vaccination. One should converse with the pediatrician in the context of the usage of this medicine in children. Growing public consciousness and the usage of FDA-consented licensed vaccines in the US contribute to the development of the vaccine, impacting the US pneumococcal vaccine market demand favorably.

Market Size and Growth:

- The US pneumococcal vaccine market size is valued at USD 5,239.27 million in 2024 and is projected to grow to USD 6,511.79 million by 2034.
- The elevated existence of pneumococcal contamination fuels the need for pneumococcal vaccines in the US.
- The market segmentation is primarily based on product type, vaccine type, and end use.

Market Competition:

The US pneumococcal vaccine market is portrayed by competitiveness. The top market contenders, such as

- Pfizer Inc.
- Merck & Co., Inc.
- Sanofi
- GlaxoSmithKline plc
- CSL Behring
- Serum Institute
- Astellas Pharma US, Inc.
- Johnson & Johnson
- Novavax, Inc.
- Vaxcyte, Inc.

Also, they support strategic alliances to enhance research potential and drive invention. Here are some of the major market developments:

- In March 2024, Vaxcyte, Inc. triumphantly recorded contenders in their trial while examining VAX-24, a pneumococcal conjugate vaccine (PCV) comprised of 24 valences that are examined amidst healthy babies.

- In October 2023, Lonza and Vaxcyte, a US clinical-stage vaccine invention firm, augmented their alliances to escalate manufacturing facility Vaxcyte's pneumococcal conjugate vaccine (PCV) contenders.

□□□□□□ □□ □ □□□□□□□ □□ □□□□ □□□□□□ □□□□□□□□:

[https://www.polarismarketresearch.com/industry-analysis/us-pneumococcal-vaccine-market/request-for-discount-pricing?utm\\_source=EIN&utm\\_medium=EIN&utm\\_campaign=EIN&utm\\_id=01](https://www.polarismarketresearch.com/industry-analysis/us-pneumococcal-vaccine-market/request-for-discount-pricing?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01)

□□□□□□ □□□□□□ □□ □□□□□□□□□□□□:

□□□□□□ □□□□□□□□□□ □□ □□□□□□□□□□□□ □□□□□□□□□□□□: The elevated existence of pneumococcal contamination and the robust dissemination framework in the US drives the market notably fueling the US pneumococcal vaccine market growth. Additionally, the escalating pneumococcal vaccinated population supplementally eases the market.

□□□□□□ □□□□□□ □□ □□□□□□□□□□□□ □□□□□□□□: The growing demand for pneumococcal vaccines is pushing notable growth in the US market due to several elements such as growing consciousness of vaccine advantages, growing existence of respiratory illnesses, healthcare policy reinforcement, and maturing population with elevated probabilities. Pneumococcal illnesses involving pneumonia, meningitis, and bloodstream contaminations are surging, particularly among susceptible groups such as elderly people, babies, and persons with eroded immune systems.

□□□□□□ □□□□□□□□ □□ □□□□□□ □□□□□□: The growing aggregate of elderly persons in the US is fueling the demand for pneumococcal vaccines. Elderly persons encounter a notably higher probability of grave pneumococcal illnesses such as pneumonia, meningitis, and bloodstream contamination because of their fragile immune systems. Thus, as the elderly population escalates and the longevity of people grows, there is an elevated requirement for prohibitive healthcare involving vaccines.

□□□□□□ □□□□ □□□□□ □□□□ □□□□□□ □□□□□□□□:

[https://www.polarismarketresearch.com/industry-analysis/us-pneumococcal-vaccine-market/inquire-before-buying?utm\\_source=EIN&utm\\_medium=EIN&utm\\_campaign=EIN&utm\\_id=01](https://www.polarismarketresearch.com/industry-analysis/us-pneumococcal-vaccine-market/inquire-before-buying?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01)

□□□□□□□□ □□□□□□□□:

By Product Type Outlook

- Prevnar 13
- Synflorix
- Pneumovax23

By Vaccine Type Outlook

- Pneumococcal conjugate vaccine (PCV)
- Pneumococcal polysaccharide vaccine (PPV)

#### By End Use Outlook

- Public Sector
- Private Sector

□□□□□□ □□□'□ □□ □□□□□□□□□□□□ □□□□□□ □□□□□□ □□□□□□□□ □□□□ □□□□□□□□□□

[US Pneumococcal Vaccine Industry](#) Projected to Reach \$6,511.79 Million by 2034, Growing at a CAGR of 2.3%

□□□□□□ □□□□ □□□□□□□□ □□□□□□□□:

Digestive & Intestinal Remedies Market:

<https://www.polarismarketresearch.com/industry-analysis/digestive-and-intestinal-remedies-market>

Arthroscopy Market:

<https://www.polarismarketresearch.com/industry-analysis/arthroscopy-market>

Angina Pectoris Drugs Market:

<https://www.polarismarketresearch.com/industry-analysis/angina-pectoris-drugs-market>

Liposomal Doxorubicin Market:

<https://www.polarismarketresearch.com/industry-analysis/liposomal-doxorubicin-market>

Surgical Sponges Market:

<https://www.polarismarketresearch.com/industry-analysis/surgical-sponges-market>

□□□□□ □□□□□□□ □□□□□□ □□□□□□□□□□ & □□□□□□□□□□□□, □□□:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

Likhil G

Polaris Market Research and Consulting

+1 929-297-9727

sales@polarismarketresearch.com

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/767793030>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.